ライフサイエンスコーパス: drug administration

1 uption in myelin structure within 2 weeks of drug administration.

2 lated stimuli, by direct stimulation, and by drug administration.

3 approval of this agent by the U.S. Food and Drug Administration.

4 ties regulated by the United States Food and Drug Administration.

5 h has come under scrutiny by the US Food and Drug Administration.

6 ghlight examples of inter-organ responses to drug administration.

7 re increased about two fold (p=0.0032) after drug administration.

8 ent, and again following the period of daily drug administration.

9 the third year after the final round of mass drug administration.

10 a guidance for industry and for the Food and Drug Administration.

11 nt for designing an optimal schedule of dual-drug administration.

12 ucosal, gastrointestinal, ungual and vaginal drug administration.

13 ug approved for treatment by the US Food and Drug Administration.

14 rded spontaneous scratching before and after drug administration.

15 omes larger under pathological conditions or drug administrations.

16 Two and 3 days after drug administration, [(18)F]FLT uptake as well as TK1 an

17 ts, indoor residual spraying, and focal mass drug administration (2,082 individuals in 432 compounds)

18 ug Development Coalition and the US Food and Drug Administration, a standardized brain tumor imaging

19 ICUs than from non-ICUs passed 2016 Food and Drug Administration accuracy criteria (p < 10) when comp

20 e patient by applying the 2016 U.S. Food and Drug Administration accuracy criteria, determining mean

21 The Food and Drug Administration Adverse Event Reporting System (FAER

22 ed knowledge-enhanced database, the Food and Drug Administration Adverse Event Reporting System Data

23 marize findings from independent US Food and Drug Administration analyses of drug resistance data fro

24 s vaccine could be used for combination mass drug administration and a mass vaccination program appro

25 logical biomarkers in rats immediately after drug administration and after the drugs had been elimina

26 udies of drugs approved by the U.S. Food and Drug Administration and commonly prescribed by primary c

27 ish intake limit proposed by the US Food and Drug Administration and Environmental Protection Agency.

28 th six approved for usage by the US Food and Drug Administration and one by the EU.

29 les, and responsibilities of the US Food and Drug Administration and the European Medicines Agency wi

30 under review for approval by the US Food and Drug Administration and the European Medicines Agency-sh

31 t (in the FST group) withdrew consent before drug administration and was excluded from analysis.

32 r spheroids formation, multiple-simultaneous drug administration, and a massive parallel testing of d

33 Cochrane Central Register, Lilacs, Food and Drug Administration, and European Medicines Agency datab

34 sing toxicology ascertained 24 h after study drug administration, and maternal and newborn serious ad

35 Serial MRI was performed immediately post drug administration, and then at day 1 (24h post), 2, 3,

36 Current US Food and Drug Administration- and European Medicines Agency-appro

37 Food and Drug Administration approaches to dissemination of infor

38 ted by monopoly rights awarded upon Food and Drug Administration approval and by patents.

39 Following the US Food and Drug Administration approval for laparoscopic gastric ba

40 mbrolizumab, have recently received Food and Drug Administration approval for the treatment of advanc

41 kpoint inhibitor have received U.S. Food and Drug Administration approval for treatment of advanced R

42 r stroke onset, despite the lack of Food and Drug Administration approval in the 3- to 4.5-hour time

43 The recent Food and Drug Administration approval of immunogenic oncolytic vi

44 h cancer that led to the initial US Food and Drug Administration approval of that agent from 2011 to

45 ies and recently in humans, with US Food and Drug Administration approval of the oncolytic herpesviru

46 tion used, despite its lacking U.S. Food and Drug Administration approval to treat ophthalmic disease

47 increased from 0 of 4488 (before US Food and Drug Administration approval) to 429 of 5253 post-PSP in

48 astic leukemia, resulting in its US Food and Drug Administration approval.

49 different classes, preferably with Food and Drug Administration approval.

50 a variety of cancers and led to US Food and Drug Administration approvals for patients with a variet

51 first-line treatment option with US Food and Drug Administration approvals for various tumor types.

52 The recent US Food and Drug Administration approvals of novel targeted therapie

53 New supplemental US Food and Drug Administration approvals, new off-label indications

54 often, and one, adalimumab, is U.S. Food and Drug Administration approved for the treatment of noninf

55 Duloxetine is US Food and Drug Administration approved for treatment of multiple c

56 n of the fumaric acid ester that is Food and Drug Administration approved for treatment of relapsing-

57 On Aug 14, 2014, the US Food and Drug Administration approved the antiangiogenesis drug b

58 In February, 2017, the US Food and Drug Administration approved the blood infection marker

59 In April 2016, the Food and Drug Administration approved the first biosimilar monocl

60 TB (MDR-TB), repurposing FDA (U.S. Food and Drug Administration) -approved drugs for development of

61 ms were generated by using the U.S. Food and Drug Administration-approved "C-View" software module.

62 Riluzole, the only US Food and Drug Administration-approved ALS drug, prolongs survival

63 Food and Drug Administration-approved anti-human cytomegalovirus

64 resistant to one or both classes of Food and Drug Administration-approved anti-influenza drugs.

65 Clofazimine is a weakly basic, Food and Drug Administration-approved antibiotic recommended by t

66 he comparative effectiveness of the Food and Drug Administration-approved BVS versus metallic EES in

67 g-repurposing screening to identify Food and Drug Administration-approved chemotherapeutic compounds

68 pproach led us to identify the U.S. Food and Drug Administration-approved compound protamine-already

69 al effectiveness and safety of U.S. Food and Drug Administration-approved devices.

70 k did not differ between current US Food and Drug Administration-approved dosing of 100-200 mg/day an

71 aB), a metabolite of cinnamon and a Food and Drug Administration-approved drug against urea cycle dis

72 In addition, a Food and Drug Administration-approved drug ameliorates the outcom

73 Adenosine is a Food and Drug Administration-approved drug, but very little is kn

74 mall molecule inhibitor of Pho84, a Food and Drug Administration-approved drug, inhibits TORC1 signal

75 database revealed that dasatinib, a Food and Drug Administration-approved drug, potently binds Hck wi

76 ere identified through screening US Food and Drug Administration-approved drugs and clinical trial co

77 ) lenalidomide and pomalidomide are Food and Drug Administration-approved drugs for the treatment of

78 high-throughput screen to identify Food and Drug Administration-approved drugs or other bioactive co

79 ng this network, we identified four Food and Drug Administration-approved drugs that selectively affe

80 molecule collection, including 1250 Food and Drug Administration-approved drugs, in a novel cell-base

81 te is 4.5, which is in the range of Food and Drug Administration-approved drugs.

82 ose Sorafenib is currently the only Food and Drug Administration-approved first-line therapy for pati

83 Daratumumab is a U.S. Food and Drug Administration-approved high-affinity monoclonal an

84 a HIV-1 RNA test (Aptima) and 20 US Food and Drug Administration-approved HIV immunoassays using 222

85 ized controlled trials of recent US Food and Drug Administration-approved immune checkpoint inhibitor

86 for phase II to IV cancer trials of Food and Drug Administration-approved immunotherapy drugs and sel

87 vation: pharmacologic (using the US Food and Drug Administration-approved inhibitor ibrutinib) and ge

88 lifetime cost-effectiveness of the Food and Drug Administration-approved lower-dose ticagrelor regim

89 We determined all US Food and Drug Administration-approved manufacturers for each form

90 e approval of riluzole, the only US Food and Drug Administration-approved medication to moderately sl

91 lth and social problem without a US Food and Drug Administration-approved medication.

92 free survival (PFS) in trials of US Food and Drug Administration-approved oncology immunotherapy drug

93 metabolites (RM) in a large set of Food and Drug Administration-approved oral medications and found

94 ions were potently inhibited by the Food and Drug Administration-approved p110delta inhibitor idelali

95 alth problem for which there are no Food and Drug Administration-approved pharmacotherapies.

96 differ from those of currently U.S. Food and Drug Administration-approved pharmacotherapies.

97 nstitutional review board- and U.S. Food and Drug Administration-approved prospective physician-initi

98 ational clinical trial following an Food and Drug Administration-approved protocol.

99 Administration of a U.S. Food and Drug Administration-approved serotonin agonist (lorcaser

100 Yet no Food and Drug Administration-approved stem cell therapies for ret

101 Today, more than 100 Food and Drug Administration-approved steroidal agents are prescr

102 f the findings is the basis of 2 US Food and Drug Administration-approved studies comparing transcath

103 Although there are no Food and Drug Administration-approved targeted therapies for mela

104 Botulinum neurotoxin B is a Food and Drug Administration-approved therapeutic toxin.

105 pid advances, resulting in multiple Food and Drug Administration-approved therapeutics that have mark

106 losporine and lifitegrast, the 2 US Food and Drug Administration-approved therapies, inhibit T-cell a

107 s; g differentiated docetaxel (a US Food and Drug Administration-approved therapy) from prednisone an

108 ays, combined with the absence of a Food and Drug Administration-approved therapy.

109 gistry captures all procedures with Food and Drug Administration-approved transcatheter valve devices

110 ections and communication by the US Food and Drug Administration are occurring, facilitating oversigh

111 These effects are time locked to drug administration, are dose related, and are transient

112 s/targeted screen-and-treat or mass or focal drug administration as malaria elimination strategies re

113 pproved in October, 2014, by the US Food and Drug Administration based on the results of the primary

114 International support for mass drug administration, bed nets, and other preventive meas

115 drugs that were approved by the US Food and Drug Administration between 1996 and 2012.

116 Recent changes to the U.S. Food and Drug Administration boxed warning for metformin will inc

117 Purpose In March 2007, a US Food and Drug Administration boxed warning was issued for erythro

118 d differing magnitude of the effects of mass drug administration, but consensus answers were reached

119 water, health and sanitation as well as mass drug administration campaigns.

120 lariasis if high population coverage of mass drug administration can be achieved and if systematic no

121 Food and Drug Administration, Centers for Medicare and Medicaid S

122 te the data necessary to support US Food and Drug Administration clearance of new diagnostic tests by

123 baseline, </= 4 at 13 weeks-the US Food and Drug Administration cleared response measure); a 30%, 50

124 A non-invasive, US Food and Drug Administration-cleared device (Neuro-Stim, Innovati

125 was to assess the potential of U.S. Food and Drug Administration-cleared devices designed for indocya

126 threshold (ultralow risk) of the US Food and Drug Administration-cleared MammaPrint 70-gene expressio

127 ripenem was demonstrated for the US Food and Drug Administration co-primary endpoints of (1) patient-

128 gehog inhibitors approved by the US Food and Drug Administration could be used for the treatment of t

129 l c-MPL agonists approved by the US Food and Drug Administration could deliver both signals to c-MPL-

130 We then varied the number of rounds of mass drug administration, coverage, duration, timing, importa

131 line characteristics, medical treatment, and drug administration data of the two groups using propens

132 r mL at week 24 according to the US Food and Drug Administration-defined snapshot algorithm.

133 of chemotherapy drugs can be used to reduce drug administration dose.

134 tains malaria immunity and suggest that mass drug administration during the dry season should not inc

135 associations between drugs of abuse and the drug administration environment have an important role i

136 and Innovation Act of 2009, the US Food and Drug Administration established an abbreviated pathway f

137 f oncology drug approvals by the US Food and Drug Administration, European Medicines Agency, and Heal

138 ends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criter

139 After study drug administration, exercise pulmonary capillary wedge

140 reatening conditions can receive US Food and Drug Administration (FDA) accelerated approval based on

141 dependent database derived from the Food and Drug Administration (FDA) Adverse Event Reporting System

142 Food and Drug Administration (FDA) Adverse Event Reporting System

143 drugs that were approved by the US Food and Drug Administration (FDA) and required pharmacogenomic b

144 cancer medicines approved by the US Food and Drug Administration (FDA) and the European Medicines Age

145 Despite Food and Drug Administration (FDA) approval of hydroxyurea to red

146 On 1 September 2017, the US Food and Drug Administration (FDA) approved gemtuzumab ozogamicin

147 Food and Drug Administration (FDA) approved sofosbuvir/velpatasvi

148 ure (LAAC) was approved by the U.S. Food and Drug Administration (FDA) as a stroke prevention alterna

149 All products fell within the US Food and Drug Administration (FDA) average bioequivalence (ABE) a

150 though in a recent ruling, the U.S. Food and Drug Administration (FDA) banned CPC from certain produc

151 tibiotics were approved by the U.S. Food and Drug Administration (FDA) between January 2010 and Decem

152 The U.S. Food and Drug Administration (FDA) continually works toward the g

153 Four assays registered with the US Food and Drug Administration (FDA) detect programmed cell death l

154 cancer and are approved by the U.S. Food and Drug Administration (FDA) for this indication.

155 ntiviral (DAA) regimens by the U.S. Food and Drug Administration (FDA) for treatment of chronic HCV i

156 opean Medicines Agency (EMA) and US Food and Drug Administration (FDA) guidance for adults was used i

157 hod was validated according to U.S. Food and Drug Administration (FDA) guidelines, which included dem

158 The Food and Drug Administration (FDA) has mandated that warnings reg

159 The Food and Drug Administration (FDA) has the authority to regulate

160 nersen/Spinraza) was approved by US Food and Drug Administration (FDA) in late 2016 and several other

161 n and Research (CDER) within the US Food and Drug Administration (FDA) is tracking the use of nanotec

162 ed of all novel agents receiving US Food and Drug Administration (FDA) licensure 2005-2012 inclusive

163 of Controlled Trials, CINAHL, U.S. Food and Drug Administration (FDA) materials, and reference lists

164 iteratively modified after initial Food and Drug Administration (FDA) Premarket Approval (PMA).

165 nsider the manner in which the U.S. Food and Drug Administration (FDA) reviews diagnostic radiopharma

166 hen Congress gave the United States Food and Drug Administration (FDA) the authority to ensure the sa

167 tions, which are approved by the US Food and Drug Administration (FDA) through various kinds of prema

168 vel therapeutics approved by the US Food and Drug Administration (FDA), and to examine whether any no

169 is Perspective discusses how the US Food and Drug Administration (FDA), the United States Pharmacopei

170 ch have not been approved by the US Food and Drug Administration (FDA), to enhance appearance and per

171 ether the off-target effects of the Food and Drug Administration (FDA)-approved anti-helminth drug ni

172 oma cells using a library of 106 US Food and Drug Administration (FDA)-approved anticancer drugs or c

173 calcineurin, with low doses of the Food and Drug Administration (FDA)-approved compound Tacrolimus,

174 We evaluated pirfenidone, a Food and Drug Administration (FDA)-approved drug for idiopathic p

175 Thus, we propose ACF, a US Food and Drug Administration (FDA)-approved drug for nononcologic

176 Furthermore, the US Food and Drug Administration (FDA)-approved drug pyrvinium delays

177 targets of 475 ( approximately 34%) Food and Drug Administration (FDA)-approved drugs and account for

178 bility to identify known targets of Food and Drug Administration (FDA)-approved drugs and it too prov

179 could be targeted by repurposed US Food and Drug Administration (FDA)-approved drugs to treat hydroc

180 c GABA signalling using zolpidem, a Food and Drug Administration (FDA)-approved GABA-positive alloste

181 of gemcitabine and several other US Food and Drug Administration (FDA)-approved oncology drugs.

182 l advocate for use of additional US Food and Drug Administration (FDA)-approved safety measures for t

183 As of mid-2016, there are no US Food and Drug Administration (FDA)-approved T cell therapeutics o

184 Currently, no Food and Drug Administration (FDA)-approved therapeutics are avai

185 s now under investigation by the US Food and Drug Administration (FDA).

186 ations have been approved by the US Food and Drug Administration for chronic weight management, and e

187 eres have been approved by the U.S. Food and Drug Administration for colorectal liver metastases, whe

188 gated one such alternative strategy for mass drug administration for elimination of lymphatic filaria

189 Mass drug administration for elimination of Plasmodium falcip

190 itional" (i.e., not approved by the Food and Drug Administration for MRI scanning).

191 approved for clinical use by the US Food and Drug Administration for other conditions, it has the pot

192 ralatrexate were approved by the US Food and Drug Administration for patients with relapsed/refractor

193 which was recently approved by the Food and Drug Administration for PBC treatment, has demonstrated

194 ement (TAVR) was approved by the US Food and Drug Administration for severe aortic stenosis in patien

195 w targeted agent approved by the US Food and Drug Administration for the treatment of chronic lymphoc

196 rin was recently approved by the US Food and Drug Administration for the treatment of FLT3-mutant acu

197 action have been approved by the US Food and Drug Administration for the treatment of relapsing forms

198 F has been recently approved by the Food and Drug Administration for the treatment of unresectable me

199 rcial tests are cleared by the U.S. Food and Drug Administration for use with extragenital swab sampl

200 active controls submitted to the US Food and Drug Administration from January 1, 2003, through Decemb

201 ) population (in accordance with US Food and Drug Administration guidance), and the modified intentio

202 adiofrequency heating was within US Food and Drug Administration guidelines.

203 In addition, the Food and Drug Administration has convened 2 Advisory Committee me

204 INTERPRETATION: Mass drug administration has the potential to reduce transmis

205 Unless elimination is achieved, mass drug administration has to be repeated regularly for sus

206 68)Ga-DOTATATE approval by the U.S. Food and Drug Administration has triggered widespread clinical in

207 Although a qualified Food and Drug Administration health claim exists for nuts and hea

208 Before study drug administration, HFpEF subjects displayed an increas

209 in conditional approval by the U.S. Food and Drug Administration in 2014.

210 Medicines Agency in 2009 and the US Food and Drug Administration in 2016.

211 derstand how to optimise the effects of mass drug administration in areas with low malaria transmissi

212 None yet are cleared by the Food and Drug Administration in the United States, although sever

213 lternative treatment to reduce the number of drug administrations in vivo and to successfully address

214 VD nonadherence, describes key U.S. Food and Drug Administration initiatives, and identifies potentia

215 The United States Food and Drug Administration is concerned about the presence of t

216 ed and if systematic non-adherence with mass drug administration is low.

217 Due to accuracy concerns, the Food and Drug Administration issued guidances to manufacturers th

218 When the US Food and Drug Administration judges the potential cardiovascular

219 provided on site, according to U.S. Food and Drug Administration labeling requirements.

220 is known about adaptations following chronic drug administration, little work has investigated how a

221 In October 2007, the Food and Drug Administration mandated significant revisions to pr

222 In 2017, 4 drugs received US Food and Drug Administration marketing approval for acute myeloid

223 chomatous trichiasis (TT) 2 years after mass drug administration (MDA) activities have ceased.

224 tent hotspots have been described after mass drug administration (MDA) for the control of schistosomi

225 Mass drug administration (MDA) is therefore considered a pote

226 The advent and proliferation of mass drug administration (MDA) programmes using the drug praz

227 Mass drug administration (MDA) with ivermectin is the corners

228 Mass drug administration (MDA) with praziquantel is the corne

229 Repeated mass drug administration (MDA) with preventive chemotherapies

230 reatments for 16,357 individuals during mass drug administration (MDA).

231 ts with laBCC or mBCC, dose and frequency of drug administration, median duration of treatment, clear

232 ment, the timing of hyperthermia relative to drug administration must be examined.

233 dels to compare the number of rounds of mass drug administration needed to achieve a prevalence of mi

234 regimen reduced the number of rounds of mass drug administration needed to reach the target prevalenc

235 ikingly reduced the number of rounds of mass drug administration needed, by about four or five, but o

236 ed in the study, with a median time to study drug administration of 3.5 hours after diagnosis of shoc

237 e onchocerciasis, primarily through the mass drug administration of ivermectin, remains challenging a

238 erapy, with 2 approvals from the US Food and Drug Administration of PD-1 inhibitors for second-line t

239 um is the only licensed adjuvant by Food and Drug Administration of USA used in many human vaccines a

240 al applications submitted to the US Food and Drug Administration Office of Hematology and Oncology Pr

241 did not identify deviations from US Food and Drug Administration or manufacturer recommendations for

242 visual analog scale serially following study drug administration or until discharge.

243 ither seasonal malaria chemoprevention, mass drug administration, or treatment of clinical malaria, c

244 The US Food and Drug Administration plans a nationwide restriction in 20

245 alaria elimination, which could include mass drug administrations, potentially in combination with iv

246 young children are largely neglected in mass drug administration programmes, but early treatment coul

247 Mass antiparasitic drug administration programs and other control strategie

248 , or ivermectin (IVM), which is used in mass drug administration programs for control of onchocercias

249 for eliminating filarial infections by mass drug administration programs may require additional tool

250 Food and Drug Administration published new, more stringent guidel

251 Food and Drug Administration published recommendations about the

252 arker-approved by the United States Food and Drug Administration-qualifying a patient to receive a sp

253 disposal, but no study reported US Food and Drug Administration-recommended disposal methods in more

254 switches, and complaints to the US Food and Drug Administration regarding generic products.

255 s Evaluation and Research of the US Food and Drug Administration regulates biologics used for diagnos

256 uirement for IVIGs, as defined in a Food and Drug Administration regulation.

257 olume deficits, but the proposed US Food and Drug Administration regulations may severely limit the a

258 Further research with improved standards of drug administration reporting is needed to help clinicia

259 However, due to inadequate drug administration reporting, it was generally unclear

260 In order to conform to the US Food and Drug Administration's accepted guidelines for ICL sizing

261 These reports originated at the US Food and Drug Administration's Adverse Event Reporting System or

262 We evaluated the US Food and Drug Administration's boxed warning of ESAs used to trea

263 Food and Drug Administration's Mini-Sentinel program.

264 regnancy and lactation using the US Food and Drug Administration's new Pregnancy and Lactation Labeli

265 ns and materials from the recent US Food and Drug Administration's Pediatric Advisory Committee meeti

266 sults of our study support the U.S. Food and Drug Administration's removal of nitarsone from the U.S.

267 The US Food and Drug Administration's updated nutrition labeling require

268 framework significantly changes the optimum drug administration schedules identified, often predicti

269 The identification of optimal drug administration schedules to battle the emergence of

270 National U.S. Food and Drug Administration Sentinel network.

271 per mL at week 48 as defined by US Food and Drug Administration snapshot algorithm (prespecified non

272 on at week 32 (as defined by the US Food and Drug Administration snapshot algorithm), protocol-define

273 sma HIV-1 RNA at week 48 (by the US Food and Drug Administration snapshot algorithm), with a prespeci

274 r mL at week 48 (assessed by the US Food and Drug Administration snapshot algorithm), with a prespeci

275 han 50 copies per mL at week 48 (US Food and Drug Administration snapshot algorithm), with a prespeci

276 mL at week 48, as defined by the US Food and Drug Administration snapshot algorithm, with a prespecif

277 mL at week 48 assessed with the US Food and Drug Administration Snapshot algorithm.

278 ive antibiotic approved by the U.S. Food and Drug Administration so far.

279 and two polymers approved by the US Food and Drug Administration: sodium hyaluronate and poly(vinylpy

280 t certain criteria specified by the Food and Drug Administration (termed "MRI-conditional" devices).

281 We track routine mass drug administration-the large-scale distribution of dewo

282 t study, was a commitment to the US Food and Drug Administration to assess the long-term safety of om

283 The final estimates used by the Food and Drug Administration to determine whether to grant emerge

284 sis of special consideration by the Food and Drug Administration to respond to an outbreak of Neisser

285 sults that were submitted to the US Food and Drug Administration to support the regulatory approval o

286 essant and has been approved by the Food and Drug Administration to treat refractory multiple scleros

287 dates of the study drugs by the US Food and Drug Administration) to May 19, 2016.

288 In contrast, the US Food and Drug Administration traditionally requires stricter crit

289 on rates (ERRs) were estimated 3 weeks after drug administration using available case analysis.

290 65%) and if systematic non-adherence to mass drug administration was low.

291 Mass drug administration was predicted to be more effective i

292 eduction in transmission resulting from mass drug administration was predicted to be temporary, and i

293 Mass drug administration was predicted to reduce transmission

294 s that have been approved by the US Food and Drug Administration was reviewed and articles related to

295 at simulates an intervention similar to mass drug administration, we argue that the observed repertoi

296 The standard treatment strategy of mass drug administration with ivermectin plus albendazole for

297 Trials submitted to the US Food and Drug Administration with more than 150 patients and in w

298 As mass drug administration with praziquantel increases in an at

299 elling to assess the potential value of mass drug administration with the triple-drug regimen for acc

300 ch used by current programmes is annual mass drug administration with two pairs of drugs with a good